EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
Vicebio
United Kingdom
- Londres, Angleterre, Royaume-Uni
- 24/09/2024
- Series B
- $100,000,000
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
- Industry Biotechnology Research
- Website https://vicebio.com/
- LinkedIn https://www.linkedin.com/company/vicebio/
Related People
Emmanuel HanonFounder
Belgium -
Brussels Metropolitan Area
Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.
Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)